Proteomic research on new urinary biomarkers of renal disease in canine leishmaniosis: Survival and monitoring response to treatment

Res Vet Sci. 2023 Aug:161:180-190. doi: 10.1016/j.rvsc.2023.06.016. Epub 2023 Jun 22.

Abstract

The objective of our study was to search for survival biomarkers (SB) and treatment response monitoring biomarkers (TRMB) in the urinary proteome of dogs with renal disease secondary to canine leishmaniosis (CanL), using UHPLC-MS/MS. The proteomic data are available via ProteomeXchange with identifier PXD042578. Initially, a group of 12 dogs was evaluated and divided into survivors (SG; n = 6) and nonsurvivors (NSG; n = 6). A total of 972 proteins were obtained from the evaluated samples. Then, bioinformatic analysis reduced them to 6 proteins like potential SB increased in the NSG, specifically, Haemoglobin subunit Alpha 1, Complement Factor I, Complement C5, Fibrinogen beta chain (fragment), Peptidase S1 domain-containing protein, and Fibrinogen gamma chain. Afterwards, SG was used to search for TRMB, studying their urine at 0, 30, and 90 days, and 9 proteins that decreased after treatment were obtained: Apolipoprotein E, Cathepsin B, Cystatin B, Cystatin-C-like, Lysozyme, Monocyte differentiation CD14, Pancreatitis-associated precursor protein, Profilin, and Protein FAM3C. Finally, enrichment analysis provided information about the biological mechanisms in which these proteins are involved. In conclusion, this study provides 15 new candidate urinary biomarkers and an improved understanding of the pathogenesis of kidney disease in CanL.

Keywords: Biomarker; Canine leishmaniosis; Miltefosine; Survival; Urinary proteome.

MeSH terms

  • Animals
  • Biomarkers
  • Dog Diseases* / metabolism
  • Dogs
  • Fibrinogen
  • Kidney Diseases* / veterinary
  • Leishmania infantum* / physiology
  • Leishmaniasis* / drug therapy
  • Leishmaniasis* / metabolism
  • Leishmaniasis* / veterinary
  • Proteomics
  • Tandem Mass Spectrometry / veterinary

Substances

  • Biomarkers
  • Fibrinogen